VCH-916

• UNSPSC Description:

  VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor. IC50 Value: Target: HCV VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient.

• Target Antigen:

  HCV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/VCH-916.html

• Smiles:

  O=C(C1=C(N([C@H]2CC[C@H](OC)CC2)C([C@H]3CC[C@H](C)CC3)=O)C=C(C4=CCCCC4)S1)O[K]

• Molecular Weight:

  497.73

• References & Citations:

  [1]Ludmila Gerber, Tania M. Welzel, Stefan Zeuzem. New therapeutic strategies in HCV: polymerase inhibitors. Liver International. 2013,33(s1): 85-92|[2]Abdelrahman S. Mayhoub. Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorganic & Medicinal Chemistry. 2012, 20 (10): 3150-3161.|[3]Debasis Dasa, Jian Honga, Shu-Hui Chena, et al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry. 2011, 19(16): 4690-4703|[4]Pierre L Beaulieu. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Informahealthcare. 2009, 19(2): 145-164|[5]Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

• Shipping Conditions:

  Room Temperature

• CAS Number:

  1200133-34-1